Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has been given an average rating of “Buy” by the four research firms that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $54.30 and last traded at $54.30, with a volume of 24959 shares. The stock had previously closed at $56.16. Analyst Upgrades and Downgrades A number of research analysts recently weighed […]
Stock analysts at StockNews.com started coverage on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. A number of other research analysts also recently commented on the company. TheStreet downgraded Ligand Pharmaceuticals from a “b-” rating to a […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Sees Large Drop in Short Interest theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totalling 825,000 shares, a drop of 6.2% from the August 31st total of 879,200 shares. Based on an average daily trading volume, of 94,200 shares, the days-to-cover […]